Sep 2026· Journal of Biological Chemistry· Vol 302, pp. 113524· 0 citations· 33 references
Medicine
TL;DR
Results indicate that B1486 is a highly potent inhibitor for blocking VprBP-mediated H2AT120p and osteoclastogenic gene silencing, as well as for overcoming osteoporosis generated by excessive osteoclast differentiation.
Abstract
Bone is a dynamic tissue that is continuously remodeled by tightly coordinated actions of bone-resorbing osteoclasts and bone-forming osteoblasts. Uncontrolled osteoclastogenesis has a severe impact on skeletal health and thus represents an important therapeutic target in osteolytic diseases. VprBP is a recently identified kinase and plays an important role in stimulating osteoclast differentiation and bone resorption through histone H2AT120 phosphorylation (H2AT120p). We previously developed B32B3 as the first VprBP inhibitor, but its high IC50 value has been a major challenge in using it for osteoclast-triggered bone diseases. In this study, we designed and characterized a series of small molecule compounds derived from B32B3 to identify a novel second-generation inhibitor of VprBP. Our initial screening of B32B3 derivatives identified three compounds, designated as B1486, B3703, and B6756, that are effective in interfering with VprBP kinase activity toward H2AT120p and RANKL-induced differentiation of osteoclast precursor cells (OCPs). However, when their cellular efficacy was systematically accessed over different concentration ranges, B1486 was more potent than B3703 and B6756 at hindering VprBP function in the process of OCP cell differentiation. Consistent with these in vitro findings, B1486 showed significantly improved inhibitory activity against VprBP-driven bone resorption and low bone mass phenotypes in our preclinical studies using zebrafish and mouse models. Taken together, our results indicate that B1486 is a highly potent inhibitor for blocking VprBP-mediated H2AT120p and osteoclastogenic gene silencing, as well as for overcoming osteoporosis generated by excessive osteoclast differentiation.
Current antiresorptive therapies reduce bone loss by eliminating osteoclasts or inhibiting their formation. However, these approaches could disrupt osteoclast-osteoblast communication and cause serious complications with long-term usage. There is a need for developing new therapies that selectively inhibit resorptive f...
Yihe Li, Qi-Hang Wu, Shengnan Qin et al.· Journal of Bone and Mineral...· 0 citations
Findings indicate that 3-MC mitigates osteoclast differentiation and oxidative stress, accompanied by downregulation of the Notch2 signaling axis, highlighting its potential as a promising therapeutic candidate for bone-related disorders.
D. Lee, Yeo Rang Cho, Ki Hyun Kim et al.· Biochemical Pharmacology· 0 citations
The homeostasis between bone formation and resorption is essential for bone maintenance. Overactivation of bone resorption can lead to a decrease in bone density, an increase in bone fragility, and the development of osteoporosis. The Receptor Activator of Nuclear Factor κ B Ligand (RANKL) is a critical driver of bone...
Zhi-Heng Chen, Ze-Hua Lu, Yi Cui et al.· The Innovation Drug Discover...· 0 citations
The findings identify CTHRC1 as a novel mediator in the bone microenvironment, providing a potential therapeutic target for inhibiting the occurrence and progression of PCa bone metastasis.
Tao Xie, Tian-Ming Peng, Qu Li et al.· Oncogene· 0 citations
The results suggest that CVB suppresses osteoclastogenesis and their resorptive function through modulation of MAPK and PI3K/AKT/FOXO1 pathways and by enhancing antioxidant defense, which has potential therapeutic value for antiosteoporosis treatment.
Qiu-Fei Li, Na Hai, Jin-Deng Liao et al.· Journal of Agricultural and...· 0 citations